EA019928B1 - Способ получения аденовирусных векторов - Google Patents
Способ получения аденовирусных векторов Download PDFInfo
- Publication number
- EA019928B1 EA019928B1 EA201170638A EA201170638A EA019928B1 EA 019928 B1 EA019928 B1 EA 019928B1 EA 201170638 A EA201170638 A EA 201170638A EA 201170638 A EA201170638 A EA 201170638A EA 019928 B1 EA019928 B1 EA 019928B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- cell
- bioreactor
- infection
- perfusion
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 95
- 238000004519 manufacturing process Methods 0.000 title claims description 41
- 239000013598 vector Substances 0.000 title description 33
- 208000015181 infectious disease Diseases 0.000 claims abstract description 102
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 89
- 230000010412 perfusion Effects 0.000 claims abstract description 77
- 239000002245 particle Substances 0.000 claims description 49
- 241000700605 Viruses Species 0.000 claims description 46
- 230000003612 virological effect Effects 0.000 claims description 20
- 238000000746 purification Methods 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 17
- 238000012258 culturing Methods 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 11
- 230000002458 infectious effect Effects 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 241000701124 Human adenovirus 35 Species 0.000 claims description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 407
- 238000005571 anion exchange chromatography Methods 0.000 description 35
- 238000004458 analytical method Methods 0.000 description 23
- 239000002609 medium Substances 0.000 description 22
- 238000011534 incubation Methods 0.000 description 20
- 238000005119 centrifugation Methods 0.000 description 19
- 229960005486 vaccine Drugs 0.000 description 17
- 238000004113 cell culture Methods 0.000 description 14
- 230000000644 propagated effect Effects 0.000 description 13
- 239000012510 hollow fiber Substances 0.000 description 12
- 239000012737 fresh medium Substances 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000003599 detergent Substances 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 239000004017 serum-free culture medium Substances 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 101000581326 Homo sapiens Mediator of DNA damage checkpoint protein 1 Proteins 0.000 description 7
- 102100027643 Mediator of DNA damage checkpoint protein 1 Human genes 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000005349 anion exchange Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 108700039887 Essential Genes Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000011210 chromatographic step Methods 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001902 propagating effect Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 229940112112 capex Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- IDLSBAANXISGEI-UHFFFAOYSA-N 2-(ethylamino)-2-phenylcyclohexan-1-one Chemical compound C=1C=CC=CC=1C1(NCC)CCCCC1=O IDLSBAANXISGEI-UHFFFAOYSA-N 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 101710114676 E1B 55 kDa protein Proteins 0.000 description 1
- 108010055325 EphB3 Receptor Proteins 0.000 description 1
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 229940021704 adenovirus vaccine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003011 anion exchange membrane Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940057324 biore Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 101150034049 cep gene Proteins 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000010972 isotropic cell growth Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000011140 membrane chromatography Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Sustainable Development (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19812208P | 2008-11-03 | 2008-11-03 | |
| EP08168181 | 2008-11-03 | ||
| PCT/EP2009/064265 WO2010060719A1 (en) | 2008-11-03 | 2009-10-29 | Method for the production of adenoviral vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201170638A1 EA201170638A1 (ru) | 2011-12-30 |
| EA019928B1 true EA019928B1 (ru) | 2014-07-30 |
Family
ID=40344776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170638A EA019928B1 (ru) | 2008-11-03 | 2009-10-29 | Способ получения аденовирусных векторов |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10041049B2 (enExample) |
| EP (1) | EP2350268B1 (enExample) |
| JP (1) | JP5770633B2 (enExample) |
| KR (1) | KR101504392B1 (enExample) |
| CN (1) | CN102203242B (enExample) |
| AU (1) | AU2009319254B2 (enExample) |
| BR (1) | BRPI0921651A2 (enExample) |
| CA (1) | CA2742474C (enExample) |
| DK (1) | DK2350268T3 (enExample) |
| EA (1) | EA019928B1 (enExample) |
| ES (1) | ES2532015T3 (enExample) |
| MX (1) | MX2011004292A (enExample) |
| NZ (1) | NZ593235A (enExample) |
| PL (1) | PL2350268T3 (enExample) |
| WO (1) | WO2010060719A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10041049B2 (en) | 2008-11-03 | 2018-08-07 | Janssen Vaccines & Prevention B.V. | Method for the production of adenoviral vectors |
| CA2777116C (en) | 2009-10-15 | 2020-09-01 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
| JP5393896B2 (ja) * | 2009-10-15 | 2014-01-22 | クルセル ホランド ベー ヴェー | アデノウイルス粒子の精製方法 |
| MX2012007936A (es) * | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus. |
| US8771709B2 (en) | 2010-09-20 | 2014-07-08 | Crucell Holland B.V. | Therapeutic vaccination against active Tuberculosis |
| BR112013004582A2 (pt) | 2010-09-27 | 2016-09-06 | Crucell Holland Bv | método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária |
| SG192611A1 (en) | 2011-02-10 | 2013-09-30 | Crucell Holland Bv | Pneumatic alternating pressure membrane cell separation system |
| US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
| SI2825640T1 (sl) | 2012-03-12 | 2016-08-31 | Crucell Holland B.V. | Šarže rekombinantnega adenovirusa s spremenjenimi konci |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| JP5805908B2 (ja) | 2012-03-22 | 2015-11-10 | クルセル ホランド ベー ヴェー | Ｒｓｖに対するワクチン |
| KR102236497B1 (ko) | 2013-04-25 | 2021-04-06 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드 |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| JP6851827B2 (ja) * | 2013-08-30 | 2021-03-31 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 細胞培養中でのウイルスの大規模製造 |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| RS58080B1 (sr) | 2014-11-04 | 2019-02-28 | Janssen Vaccines & Prevention Bv | Terapeutske vakcine protiv hpv16 |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| EA039065B1 (ru) | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| US9663766B2 (en) | 2015-07-24 | 2017-05-30 | Bio-Rad Laboratories, Inc. | Methods for purifying adenovirus vectors |
| JP6470872B2 (ja) | 2015-08-20 | 2019-02-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 治療用ｈｐｖ１８ワクチン |
| IL262108B2 (en) | 2016-04-05 | 2023-04-01 | Janssen Vaccines Prevention B V | Soluble pre-fusion rsv f proteins are stabilized |
| JP7233928B2 (ja) | 2016-04-05 | 2023-03-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｒｓｖに対するワクチン |
| US10358626B2 (en) * | 2016-04-12 | 2019-07-23 | Artemis Biosystems, Inc. | Perfusion filtration systems |
| JP7053491B2 (ja) | 2016-05-02 | 2022-04-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 治療用ｈｐｖワクチン組み合わせ |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| CN109311946A (zh) | 2016-05-30 | 2019-02-05 | 扬森疫苗与预防公司 | 稳定化的融合前rsv f蛋白 |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| WO2018011196A1 (en) | 2016-07-14 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
| CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
| AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
| WO2019086450A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| CN111372943B (zh) | 2017-10-31 | 2023-12-05 | 扬森疫苗与预防公司 | 腺病毒及其用途 |
| WO2019086466A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| WO2019086461A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| AU2018383679B2 (en) * | 2017-12-11 | 2025-10-09 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
| CN110317832B (zh) | 2018-03-28 | 2022-07-05 | 西比曼生物科技（香港）有限公司 | Gmp级规模化制备重组慢病毒载体的纯化制剂的方法 |
| CN110317791A (zh) | 2018-03-29 | 2019-10-11 | 西比曼生物科技（香港）有限公司 | Gmp级无血清悬浮细胞大规模生产慢病毒的方法 |
| WO2019209632A1 (en) | 2018-04-24 | 2019-10-31 | Merck Sharp & Dohme Corp. | Scalable chromatography process for purification of human cytomegalovirus |
| MX2021005607A (es) | 2018-11-13 | 2021-06-30 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del vrs estabilizadas. |
| BR112022000061A2 (pt) * | 2019-07-01 | 2022-05-24 | Ology Bioservices Inc | Método para o cultivo de células aderentes em um bioreator multiparalelo |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
| CA3195177A1 (en) | 2020-10-07 | 2022-04-14 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i) |
| KR20230165275A (ko) | 2021-04-01 | 2023-12-05 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합 전 piv3 f 단백질 |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4448802A1 (en) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| WO2024061753A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric class i fusion proteins |
| WO2024061757A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| WO2024074584A1 (en) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
| WO2024190895A1 (ja) | 2023-03-15 | 2024-09-19 | 東レ株式会社 | フィルターユニット、精製装置及び精製液の製造方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005080556A2 (en) * | 2004-02-23 | 2005-09-01 | Crucell Holland B.V. | Virus purification methods |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04241381A (ja) | 1991-01-16 | 1992-08-28 | Brother Ind Ltd | 電子学習機 |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| ATE336587T1 (de) | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| IL160406A0 (en) | 1995-06-15 | 2004-07-25 | Crucell Holland Bv | A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products |
| WO1997008298A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
| IL127692A0 (en) | 1996-07-01 | 1999-10-28 | Rhone Poulenc Rorer Sa | Method for producing recombinant adenovirus |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| WO1998022588A2 (en) | 1996-11-20 | 1998-05-28 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| CA2283253A1 (en) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Adenovirus e1-complementing cell lines |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| IL137510A0 (en) | 1998-02-17 | 2001-07-24 | Schering Corp | Compositions comprising viruses and methods for concentrating virus preparations |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| IL139040A0 (en) | 1998-04-22 | 2001-11-25 | Genvec Inc | Efficient purification of adenovirus |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| US20040043489A1 (en) | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
| DK1133316T3 (da) | 1998-11-16 | 2009-05-25 | Introgen Therapeutics Inc | Adenovirus-formulering til genterapi |
| NZ512504A (en) | 1998-12-31 | 2004-01-30 | Aventis Pharma Sa | Method for separating viral particles |
| JP4802366B2 (ja) | 1999-02-22 | 2011-10-26 | トランスジェン・ソシエテ・アノニム | 精製ウイルス調製物の取得方法 |
| ES2372823T3 (es) | 1999-05-17 | 2012-01-26 | Crucell Holland B.V. | Adenovirus recombinante del serotipo ad11. |
| US20050232900A1 (en) | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| WO2003104467A1 (en) | 2002-04-25 | 2003-12-18 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
| DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
| JP5118798B2 (ja) | 2000-03-07 | 2013-01-16 | メルク・シャープ・エンド・ドーム・コーポレイション | アデノウイルス製剤 |
| DE60138403D1 (de) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
| US20020064860A1 (en) | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
| CA2469623C (en) | 2001-12-12 | 2012-05-29 | F H Faulding & Co Limited | Composition for the preservation of viruses |
| EP1516055A4 (en) | 2002-01-24 | 2007-08-08 | Scripps Research Inst | FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS |
| US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
| EP1497440B1 (en) | 2002-04-25 | 2008-08-20 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| ATE360683T1 (de) | 2002-05-14 | 2007-05-15 | Merck & Co Inc | Verfahren zur reinigung von adenovirus |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| AU2003288273A1 (en) | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| NZ539813A (en) | 2002-12-17 | 2008-04-30 | Crucell Holland Bv | A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6 |
| US20080124360A1 (en) | 2003-01-24 | 2008-05-29 | Seggern Daniel J Von | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
| CN1863918B (zh) | 2003-10-02 | 2011-03-30 | 克鲁塞尔荷兰公司 | 用于重组腺病毒的包装细胞 |
| CA2557046A1 (en) * | 2004-03-05 | 2005-10-13 | John Crowley | Process for cell culturing by continuous perfusion and alternating tangential flow |
| DK1773976T4 (da) | 2004-06-04 | 2020-02-10 | Global Life Sciences Solutions Usa Llc | Engangsbioreaktorsystemer og -fremgangsmåder |
| AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
| EA016648B1 (ru) | 2004-10-14 | 2012-06-29 | Круселл Холланд Б.В. | Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии |
| CN102220357B (zh) | 2004-11-16 | 2013-12-25 | 克鲁塞尔荷兰公司 | 包含重组病毒载体的多价疫苗 |
| JP2008538894A (ja) | 2005-02-11 | 2008-11-13 | メルク エンド カムパニー インコーポレーテッド | アデノウイルス血清型２６ベクター、核酸およびそれにより製造されたウイルス |
| CA2602944C (en) | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| JP2008541730A (ja) | 2005-05-23 | 2008-11-27 | ヴァクシン インコーポレイテッド | 高力価かつ複製コンピテントアデノウイルス不含である組換えアデノウイルスベクターの迅速な作成法 |
| WO2007010409A2 (en) | 2005-07-22 | 2007-01-25 | Pergo (Europe) Ab | Flooring system including a preglue |
| US20070178115A1 (en) | 2005-08-15 | 2007-08-02 | Tang De-Chu C | Immunization of avians by administration of non-replicating vectored vaccines |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| EP1998804B1 (en) | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| US9364525B2 (en) | 2006-07-18 | 2016-06-14 | Glaxosmithkline Biologicals Sa | Vaccines for malaria |
| PL2137210T3 (pl) | 2007-03-02 | 2017-06-30 | Glaxosmithkline Biologicals Sa | Nowy sposób i kompozycje |
| US9109193B2 (en) | 2007-07-30 | 2015-08-18 | Ge Healthcare Bio-Sciences Corp. | Continuous perfusion bioreactor system |
| CN101855371A (zh) | 2007-11-14 | 2010-10-06 | 张惇杰 | 制备用于锂离子电池应用的空气敏感性电极材料的方法和装置 |
| WO2009117134A2 (en) | 2008-03-21 | 2009-09-24 | National Institutes Of Health | Aerosolized genetic vaccines and methods of use |
| US10041049B2 (en) | 2008-11-03 | 2018-08-07 | Janssen Vaccines & Prevention B.V. | Method for the production of adenoviral vectors |
| SI2454364T1 (sl) | 2009-07-16 | 2014-08-29 | Crucell Holland B.V. | Izdelava polio virusa v visokih titrih za izdelavo cepiva |
| CA2777116C (en) | 2009-10-15 | 2020-09-01 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
| MX2012007936A (es) | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus. |
| US20120315696A1 (en) | 2010-02-15 | 2012-12-13 | Alfred Luitjens | METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS |
-
2009
- 2009-10-29 US US13/126,978 patent/US10041049B2/en active Active
- 2009-10-29 EP EP09744140.6A patent/EP2350268B1/en active Active
- 2009-10-29 ES ES09744140.6T patent/ES2532015T3/es active Active
- 2009-10-29 EA EA201170638A patent/EA019928B1/ru not_active IP Right Cessation
- 2009-10-29 NZ NZ593235A patent/NZ593235A/xx not_active IP Right Cessation
- 2009-10-29 BR BRPI0921651-0A patent/BRPI0921651A2/pt not_active Application Discontinuation
- 2009-10-29 WO PCT/EP2009/064265 patent/WO2010060719A1/en not_active Ceased
- 2009-10-29 KR KR1020117010793A patent/KR101504392B1/ko not_active Expired - Fee Related
- 2009-10-29 CA CA2742474A patent/CA2742474C/en active Active
- 2009-10-29 CN CN2009801438951A patent/CN102203242B/zh not_active Expired - Fee Related
- 2009-10-29 JP JP2011533718A patent/JP5770633B2/ja not_active Expired - Fee Related
- 2009-10-29 AU AU2009319254A patent/AU2009319254B2/en not_active Ceased
- 2009-10-29 MX MX2011004292A patent/MX2011004292A/es active IP Right Grant
- 2009-10-29 PL PL09744140T patent/PL2350268T3/pl unknown
- 2009-10-29 DK DK09744140.6T patent/DK2350268T3/en active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005080556A2 (en) * | 2004-02-23 | 2005-09-01 | Crucell Holland B.V. | Virus purification methods |
Non-Patent Citations (8)
| Title |
|---|
| ALTARAS N. E. ET AL.: "Production and Formulation of Adenovirus Vectors", ADVANCES IN BIOCHEMICAL ENGINEERING, BIOTECHNOLOGY, SPRINGER, BERLIN, DE, vol. 99, 1 November 2005 (2005-11-01), pages 193-260, XP009105897, ISSN: 0724-6145, the whole document, page 237, second paragraph, page 238, second paragraph, page 251, paragraph 2 - page 252, paragraph 2; table 2 * |
| HAVENGA M. ET AL.: "Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 87, no. Part 8, 1 August 2006 (2006-08-01), pages 2135-2143, XP002496482, ISSN: 0022-1317, whole document; page 2139; fig. 3 * |
| HENRY OLIVIER ET AL.: "Insights into adenoviral vector production kinetics in acoustic filter-based perfusion cultures", BIOTECHNOLOGY AND BIOENGINEERING, vol. 86, no. 7, 30 June 2004 (2004-06-30), pages 765-774, XP008102488, ISSN: 0006-3592, the whole document * |
| MARANGA LUIS ET AL.: "Characterization of changes in PER.C6 (TM) cellular metabolism during growth and propagation of a replication-deficient adenovirus vector", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 90, no. 5, 1 June 2005 (2005-06-01), pages 645-655, XP002496483, ISSN: 0006-3592, the whole document * |
| SUBRAMANIAN S. ET AL.: "Pilot-scale adenovirus seed production through concurrent virus release and concentrati on by holl ow fiber filtration", BIOTECHNOLOGY PROGRESS MAY/JUNE 2005, AMERICAN CHEMICAL SOCIETY US, vol. 21, no. 3, May 2005 (2005-05), pages 851-859, XP002516027, page 851, 852 * |
| XIE LIANGZHI ET AL.: "Large-scale propagation of a repl icati on-defective adenovirus vector insti rred-tank bioreactor PER.C6TM cell culture under sparging conditions", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 83, no. 1, 5 July 2003 (2003-07-05), pages 45-52, XP002296365, ISSN: 0006-3592, page 45, 46 * |
| YALLOP С. ET AL.: "Per.C6 cells for the manufacture of biopharmaceutical proteins", MODERN BIOPHARMACEUTICALS: DESIGN, DEVELOPMENT AND OPTIMIZATION, WILEY-VCH, WEINHEIM, vol. 3, 1 January 2005 (2005-01-01), pages 779-807, XP008102484 ISBN: 978-3-527-31184-2, page 794-796; the whole document * |
| YUK INN H. Y. ET AL.: "Perfusion cultures of human tumor cells: A scalable production platform for oncolytic adenoviral vectors", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 86, no. 6, 20 June 2004 (2004-06-20), pages 637-642, XP002496481 ISSN: 0006-3592, page 638, right-hand side column, last paragraph; the whole document * |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201170638A1 (ru) | 2011-12-30 |
| CA2742474C (en) | 2016-05-31 |
| AU2009319254A1 (en) | 2010-06-03 |
| PL2350268T3 (pl) | 2015-05-29 |
| US20110207202A1 (en) | 2011-08-25 |
| CN102203242B (zh) | 2013-06-12 |
| KR101504392B1 (ko) | 2015-03-19 |
| US10041049B2 (en) | 2018-08-07 |
| JP5770633B2 (ja) | 2015-08-26 |
| ES2532015T3 (es) | 2015-03-23 |
| CA2742474A1 (en) | 2010-06-03 |
| HK1160664A1 (en) | 2012-08-10 |
| EP2350268A1 (en) | 2011-08-03 |
| NZ593235A (en) | 2013-02-22 |
| JP2012507270A (ja) | 2012-03-29 |
| EP2350268B1 (en) | 2014-12-24 |
| AU2009319254B2 (en) | 2015-04-30 |
| KR20110093793A (ko) | 2011-08-18 |
| WO2010060719A1 (en) | 2010-06-03 |
| DK2350268T3 (en) | 2015-03-23 |
| BRPI0921651A2 (pt) | 2015-08-18 |
| MX2011004292A (es) | 2011-05-31 |
| CN102203242A (zh) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA019928B1 (ru) | Способ получения аденовирусных векторов | |
| ES2578514T3 (es) | Método para la producción de vectores adenovíricos | |
| EP1268748B1 (en) | Method of producing adenoviral vector stocks | |
| US20180080010A1 (en) | Method for the production of ad26 adenoviral vectors | |
| US20050118701A1 (en) | Large scale methods of producing adenovirus and adenovirus seed stocks | |
| TW202237831A (zh) | 生產腺病毒之方法 | |
| HK1160664B (en) | Method for the production of adenoviral vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |